Stockscreener 앱 받기
5.54
3.75%
0.20
시간 외 거래:
5.59
0.05
+0.90%
전일 마감가:
$5.34
열려 있는:
$5.48
하루 거래량:
6.76M
Relative Volume:
1.78
시가총액:
$1.70B
수익:
$248.37M
순이익/손실:
$11.74M
주가수익비율:
110.80
EPS:
0.05
순현금흐름:
$18.24M
1주 성능:
+20.70%
1개월 성능:
+38.85%
6개월 성능:
+7.57%
1년 성능:
-8.13%
1일 변동 폭
$5.40
$5.83
1주일 범위
$5.22
$6.199
52주 변동 폭
$3.3812
$7.63
맨카인드 Stock (MNKD) Company Profile
명칭
Mannkind Corp
전화
818-661-5000
주소
1 CASPER STREET, DANBURY, CA
MNKD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
5.54 | 1.64B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
맨카인드 Stock (MNKD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-16 | 재개 | H.C. Wainwright | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-10 | 개시 | Wedbush | Outperform |
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-12-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-10-10 | 개시 | Wedbush | Outperform |
| 2021-05-14 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 개시 | Oppenheimer | Outperform |
| 2019-10-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 개시 | BTIG Research | Buy |
| 2019-03-04 | 개시 | SVB Leerink | Outperform |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2018-02-28 | 다운그레이드 | Maxim Group | Hold → Sell |
| 2017-11-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-10 | 개시 | H.C. Wainwright | Buy |
| 2017-10-06 | 재확인 | Maxim Group | Buy |
| 2017-08-11 | 개시 | Maxim Group | Buy |
| 2016-05-10 | 재확인 | Piper Jaffray | Underweight |
| 2016-05-10 | 재확인 | RBC Capital Mkts | Underperform |
| 2016-01-06 | 재확인 | Piper Jaffray | Underweight |
| 2016-01-06 | 재확인 | RBC Capital Mkts | Underperform |
| 2015-11-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | 다운그레이드 | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-05-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 재확인 | MLV & Co | Hold |
| 2015-04-16 | 재확인 | RBC Capital Mkts | Outperform |
모두보기
맨카인드 주식(MNKD)의 최신 뉴스
MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline - MSN
MannKind Shares Soar to Over 8-Year Highs on United Therapeutics’ Tyvaso Revenue Surge: Retail Is Optimistic - MSN
Can MannKind Corporation grow without external fundingJuly 2025 Review & Stock Market Timing Techniques - خودرو بانک
Can MannKind Corporation outperform in the next rallyJuly 2025 Fed Impact & Short-Term Trading Alerts - خودرو بانک
MannKind Gets A Price Bump As Pipeline Progresses - Finimize
Can trapped investors hope for a rebound in MannKind CorporationWeekly Risk Summary & AI Enhanced Trading Signals - Newser
MannKind Corporation stock prediction for this weekMarket Risk Analysis & High Conviction Investment Ideas - Newser
What candlestick patterns are forming on MannKind CorporationWatch List & Free Verified High Yield Trade Plans - Newser
MannKind at Cantor Global Healthcare Conference: Strategic Growth Insights - Investing.com
Has MannKind Corporation formed a bullish divergenceJuly 2025 Gainers & Expert Approved Momentum Trade Ideas - Newser
Published on: 2025-09-04 00:37:09 - Newser
Will MannKind Corporation outperform small cap indexesJuly 2025 PostEarnings & Capital Efficient Trading Techniques - خودرو بانک
MannKind at Wells Fargo Conference: Strategic Diversification Unveiled - Investing.com
MannKind Corporation recovery potential after sell offTrade Exit Summary & Community Consensus Trade Signals - Newser
MannKind stock price target raised to $11 by H.C. Wainwright on Tyvaso success - Investing.com
MannKind (MNKD) Expands United Therapeutics Deal Can New Platform Revenues Transform Its Long-Term Story? - simplywall.st
What to expect from MannKind Corporation in the next 30 daysBond Market & Weekly Chart Analysis and Trade Guides - Newser
MannKind Corporation (NASDAQ:MNKD) Looks Just Right With A 53% Price Jump - simplywall.st
Can MannKind Corporation recover in the next quarterWeekly Market Outlook & Accurate Technical Buy Alerts - Newser
Mannkind Corporation shares rise 1.22% premarket after United Therapeutics' drug Tyvaso shows significant lung function improvement. - AInvest
Published on: 2025-09-03 02:55:27 - Newser
Forecasting MannKind Corporation price range with options dataIPO Watch & Weekly Watchlist for Hot Stocks - Newser
Combining machine learning predictions for MannKind CorporationJuly 2025 Recap & Safe Capital Investment Plans - Newser
Can MannKind Corporation ride the EV waveShare Buyback & Target Return Focused Picks - خودرو بانک
Trend analysis for MannKind Corporation this weekMarket Activity Report & Real-Time Volume Spike Alerts - Newser
Does MannKind Corporation show high probability of reboundJuly 2025 Breakouts & Real-Time Market Trend Scan - Newser
Historical volatility pattern of MannKind Corporation visualized2025 Market Overview & Smart Allocation Stock Reports - Newser
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results - Stocktwits
Is MannKind Corporation stock a buy or sellQuarterly Performance Summary & Low Drawdown Momentum Ideas - خودرو بانک
Leerink Partners Reiterates a Buy Rating on MannKind Corporation (MNKD), Keeps the PT at $7 - MSN
Applying chart zones and confluence areas to MannKind CorporationPortfolio Growth Summary & Weekly Sector Rotation Insights - Newser
What MACD and RSI say about MannKind CorporationMarket Sentiment Review & Verified Momentum Watchlists - Newser
Mannkind (MNKD) Surges 25% on Strategic Acquisition and Financing Hints – What’s Next? - AInvest
Full technical analysis of MannKind Corporation stockJuly 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - Newser
United Therapeutics Shares Surge on Strong Lung-Drug Trial Results - citybiz
MannKind Corporation Reversal Rally May Surprise Bears getLinesFromResByArray error: size == 0 - kangso.co.kr
What momentum shifts mean for MannKind CorporationDay Trade & Fast Momentum Entry Tips - Newser
United’s Tyvaso surprise in IPF potentially opens $4B market - BioWorld MedTech
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - inkl
MannKind Stock Surges Anew: Buy or Hold? - StocksToTrade
Mannkind Soars 38.13% on Strategic Acquisition of scPharmaceuticals - AInvest
MNKD Shares Plunge: Should Investors Worry? - timothysykes.com
How to integrate MannKind Corporation into portfolio analysis toolsJuly 2025 EndofMonth & Real-Time Sentiment Analysis - Newser
Is MannKind Corporation currently under institutional pressureGap Up & Safe Entry Trade Reports - خودرو بانک
H.C. Wainwright Reiterates a Buy Rating on MannKind Corporation (MNKD) - MSN
Applying big data sentiment scoring on MannKind CorporationJuly 2025 PostEarnings & Safe Entry Zone Tips - Newser
How MannKind Corporation stock performs during market volatilityTrade Exit Summary & Risk Controlled Stock Alerts - Newser
How to recover losses in MannKind Corporation stockWall Street Watch & Verified Technical Signals - Newser
MannKind Corporation Could See a Relief Rally From Support getLinesFromResByArray error: size == 0 - 강소기업뉴스
Candlestick signals on MannKind Corporation stock todayBond Market & Safe Capital Investment Plans - Newser
맨카인드 (MNKD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
맨카인드 주식 (MNKD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Thomson David | EVP Genl Counsel & Secretary |
Jul 16 '25 |
Sale |
3.94 |
7,466 |
29,416 |
841,719 |
1.40%
자본화:
|
볼륨(24시간):